Everads-Therapy is developing a revolutionary drug and cell delivery system for injectable therapies to the back of the eye.
Posterior segment diseases of the eye are sight threatening and hard to treat due to their chronic and relapsing nature. Everad`s delivery system will be superior to Intravitreal injections and other techniques for drug delivery to the back of the eye by targeting the delivery of therapies into the extravascular matrix of the choroid.
Indeed, from initial in-vivo proof-of-concept studies using a model of rabbit, Everad`s delivery system has demonstrated highly promising data.
Approximately 18 million Intravitreal injections of anti-VEGF agents applied in 2014 WW
Global cost of visual impairment due to AMD alone is $343 billion, including $255 billion in direct health costs
The incidence of visual impairment
will increase due to an aging population and increased diabetes prevalence